An esterase-activatable curcumin prodrug for tumor-targeting therapy
A tumor-targeting therapy strategy is urgently needed to increase the accumulation of drugs in tumors and reduce the side effects in normal tissues. Herein, we developed an esterase-activatable curcumin prodrug Cur-RGD for tumor-targeting therapy. Armed with the tumor-targeting RGD peptide and in si...
Gespeichert in:
| Veröffentlicht in: | Chemical communications (Cambridge, England) England), 2022-12, Vol.58 (96), p.13329-13332 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 13332 |
|---|---|
| container_issue | 96 |
| container_start_page | 13329 |
| container_title | Chemical communications (Cambridge, England) |
| container_volume | 58 |
| creator | Liu, Li Zhang, Lele Tao, Menglin Wang, Minghui Dong, Ling Hai, Zijuan |
| description | A tumor-targeting therapy strategy is urgently needed to increase the accumulation of drugs in tumors and reduce the side effects in normal tissues. Herein, we developed an esterase-activatable curcumin prodrug
Cur-RGD
for tumor-targeting therapy. Armed with the tumor-targeting RGD peptide and
in situ
esterase-triggered drug release, this prodrug
Cur-RGD
can efficiently improve the therapeutic effect of curcumin in tumors.
Armed with a tumor-targeting RGD peptide and an
in situ
esterase-triggered drugrelease, prodrug
Cur-RGD
can efficiently improve the therapeutic effect ofcurcumin in tumors. |
| doi_str_mv | 10.1039/d2cc03952d |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1039_D2CC03952D</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2743510987</sourcerecordid><originalsourceid>FETCH-LOGICAL-c203t-b33c38e0c2ea197137a473c8830645960a5bfc5042fd07b25925465d1e9ed013</originalsourceid><addsrcrecordid>eNpFkL1PwzAQxS0EEqWwsCNFYkMy2D47jscq5UuqxNKBLXIcp6Rqk3J2kPrf41IEt7wbfu_u6RFyzdk9Z2AeGuFcUiWaEzLhkEuqZPF-etiVoRqkOicXIaxZGq6KCZnP-syH6NEGT62L3ZeNtt74zI3oxm3XZzscGhxXWTtgFsftgDRaXPnY9assfiTjbn9Jzlq7Cf7qV6dk-fS4LF_o4u35tZwtqBMMIq0BHBSeOeEtN5qDtlKDKwpguVQmZ1bVrVNMirZhuhbKCCVz1XBvfMM4TMnt8WyK9Dmm1NV6GLFPHyuhJSjOTKETdXekHA4hoG-rHXZbi_uKs-pQUjUXZflT0jzBN0cYg_vj_kuEbw7wYt8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2743510987</pqid></control><display><type>article</type><title>An esterase-activatable curcumin prodrug for tumor-targeting therapy</title><source>Royal Society Of Chemistry Journals 2008-</source><source>Alma/SFX Local Collection</source><creator>Liu, Li ; Zhang, Lele ; Tao, Menglin ; Wang, Minghui ; Dong, Ling ; Hai, Zijuan</creator><creatorcontrib>Liu, Li ; Zhang, Lele ; Tao, Menglin ; Wang, Minghui ; Dong, Ling ; Hai, Zijuan</creatorcontrib><description>A tumor-targeting therapy strategy is urgently needed to increase the accumulation of drugs in tumors and reduce the side effects in normal tissues. Herein, we developed an esterase-activatable curcumin prodrug
Cur-RGD
for tumor-targeting therapy. Armed with the tumor-targeting RGD peptide and
in situ
esterase-triggered drug release, this prodrug
Cur-RGD
can efficiently improve the therapeutic effect of curcumin in tumors.
Armed with a tumor-targeting RGD peptide and an
in situ
esterase-triggered drugrelease, prodrug
Cur-RGD
can efficiently improve the therapeutic effect ofcurcumin in tumors.</description><identifier>ISSN: 1359-7345</identifier><identifier>EISSN: 1364-548X</identifier><identifier>DOI: 10.1039/d2cc03952d</identifier><language>eng</language><publisher>Cambridge: Royal Society of Chemistry</publisher><subject>Side effects ; Therapy ; Tumors</subject><ispartof>Chemical communications (Cambridge, England), 2022-12, Vol.58 (96), p.13329-13332</ispartof><rights>Copyright Royal Society of Chemistry 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c203t-b33c38e0c2ea197137a473c8830645960a5bfc5042fd07b25925465d1e9ed013</cites><orcidid>0000-0002-2049-1017</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Liu, Li</creatorcontrib><creatorcontrib>Zhang, Lele</creatorcontrib><creatorcontrib>Tao, Menglin</creatorcontrib><creatorcontrib>Wang, Minghui</creatorcontrib><creatorcontrib>Dong, Ling</creatorcontrib><creatorcontrib>Hai, Zijuan</creatorcontrib><title>An esterase-activatable curcumin prodrug for tumor-targeting therapy</title><title>Chemical communications (Cambridge, England)</title><description>A tumor-targeting therapy strategy is urgently needed to increase the accumulation of drugs in tumors and reduce the side effects in normal tissues. Herein, we developed an esterase-activatable curcumin prodrug
Cur-RGD
for tumor-targeting therapy. Armed with the tumor-targeting RGD peptide and
in situ
esterase-triggered drug release, this prodrug
Cur-RGD
can efficiently improve the therapeutic effect of curcumin in tumors.
Armed with a tumor-targeting RGD peptide and an
in situ
esterase-triggered drugrelease, prodrug
Cur-RGD
can efficiently improve the therapeutic effect ofcurcumin in tumors.</description><subject>Side effects</subject><subject>Therapy</subject><subject>Tumors</subject><issn>1359-7345</issn><issn>1364-548X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpFkL1PwzAQxS0EEqWwsCNFYkMy2D47jscq5UuqxNKBLXIcp6Rqk3J2kPrf41IEt7wbfu_u6RFyzdk9Z2AeGuFcUiWaEzLhkEuqZPF-etiVoRqkOicXIaxZGq6KCZnP-syH6NEGT62L3ZeNtt74zI3oxm3XZzscGhxXWTtgFsftgDRaXPnY9assfiTjbn9Jzlq7Cf7qV6dk-fS4LF_o4u35tZwtqBMMIq0BHBSeOeEtN5qDtlKDKwpguVQmZ1bVrVNMirZhuhbKCCVz1XBvfMM4TMnt8WyK9Dmm1NV6GLFPHyuhJSjOTKETdXekHA4hoG-rHXZbi_uKs-pQUjUXZflT0jzBN0cYg_vj_kuEbw7wYt8</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Liu, Li</creator><creator>Zhang, Lele</creator><creator>Tao, Menglin</creator><creator>Wang, Minghui</creator><creator>Dong, Ling</creator><creator>Hai, Zijuan</creator><general>Royal Society of Chemistry</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>L7M</scope><orcidid>https://orcid.org/0000-0002-2049-1017</orcidid></search><sort><creationdate>20221201</creationdate><title>An esterase-activatable curcumin prodrug for tumor-targeting therapy</title><author>Liu, Li ; Zhang, Lele ; Tao, Menglin ; Wang, Minghui ; Dong, Ling ; Hai, Zijuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c203t-b33c38e0c2ea197137a473c8830645960a5bfc5042fd07b25925465d1e9ed013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Side effects</topic><topic>Therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Li</creatorcontrib><creatorcontrib>Zhang, Lele</creatorcontrib><creatorcontrib>Tao, Menglin</creatorcontrib><creatorcontrib>Wang, Minghui</creatorcontrib><creatorcontrib>Dong, Ling</creatorcontrib><creatorcontrib>Hai, Zijuan</creatorcontrib><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Chemical communications (Cambridge, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Li</au><au>Zhang, Lele</au><au>Tao, Menglin</au><au>Wang, Minghui</au><au>Dong, Ling</au><au>Hai, Zijuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An esterase-activatable curcumin prodrug for tumor-targeting therapy</atitle><jtitle>Chemical communications (Cambridge, England)</jtitle><date>2022-12-01</date><risdate>2022</risdate><volume>58</volume><issue>96</issue><spage>13329</spage><epage>13332</epage><pages>13329-13332</pages><issn>1359-7345</issn><eissn>1364-548X</eissn><abstract>A tumor-targeting therapy strategy is urgently needed to increase the accumulation of drugs in tumors and reduce the side effects in normal tissues. Herein, we developed an esterase-activatable curcumin prodrug
Cur-RGD
for tumor-targeting therapy. Armed with the tumor-targeting RGD peptide and
in situ
esterase-triggered drug release, this prodrug
Cur-RGD
can efficiently improve the therapeutic effect of curcumin in tumors.
Armed with a tumor-targeting RGD peptide and an
in situ
esterase-triggered drugrelease, prodrug
Cur-RGD
can efficiently improve the therapeutic effect ofcurcumin in tumors.</abstract><cop>Cambridge</cop><pub>Royal Society of Chemistry</pub><doi>10.1039/d2cc03952d</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-2049-1017</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-7345 |
| ispartof | Chemical communications (Cambridge, England), 2022-12, Vol.58 (96), p.13329-13332 |
| issn | 1359-7345 1364-548X |
| language | eng |
| recordid | cdi_crossref_primary_10_1039_D2CC03952D |
| source | Royal Society Of Chemistry Journals 2008-; Alma/SFX Local Collection |
| subjects | Side effects Therapy Tumors |
| title | An esterase-activatable curcumin prodrug for tumor-targeting therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T09%3A21%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20esterase-activatable%20curcumin%20prodrug%20for%20tumor-targeting%20therapy&rft.jtitle=Chemical%20communications%20(Cambridge,%20England)&rft.au=Liu,%20Li&rft.date=2022-12-01&rft.volume=58&rft.issue=96&rft.spage=13329&rft.epage=13332&rft.pages=13329-13332&rft.issn=1359-7345&rft.eissn=1364-548X&rft_id=info:doi/10.1039/d2cc03952d&rft_dat=%3Cproquest_cross%3E2743510987%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2743510987&rft_id=info:pmid/&rfr_iscdi=true |